12:00 AM
Jul 22, 2013
 |  BioCentury  |  Emerging Company Profile

GrayBug: Long view in AMD

GrayBug developing extended-release anti-angiogenic therapy for AMD

GrayBug LLC is looking to treat age-related macular degeneration by combining two technologies - a small molecule therapeutic and an extended-release polymer carrier - to achieve sustained inhibition of hypoxia-inducible factor 1 activity in the retina.

Hypoxia-inducible factor 1 (HIF1) is a transcription factor that upregulates VEGF and other angiogenic proteins in response to low oxygen levels.

GrayBug co-founder and COO Christy Wyskiel said the company's lead candidate, GB-AMD101, contains a small molecule inhibitor of HIF1 activity discovered in the laboratory of co-founder Peter Campochiaro, professor of ophthalmology at Johns Hopkins University.

Campochiaro's team reported in a 2010 paper in FASEB Journal that digoxin reduced HIF1 levels and prevented neovascularization in mouse models of ischemic...

Read the full 576 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >